Innovative Technology Cagent Vascular's proprietary Serration Remodeling Therapy (SRT) and the flagship Serranator® PTA Serration Balloon Catheter position it as a leader in advanced vessel dilation technologies, offering a compelling value proposition for healthcare providers seeking improved long-term patency and better patient outcomes.

Recent Product Launches The launch of the Serranator SL-PRO for chronic limb-threatening ischemia and pedal disease indicates a strategic focus on expanding product applications and addressing critical endovascular treatment needs, presenting sales expansion opportunities within specialized vascular centers.

Strategic Partnerships Collaborations with companies like 3comma Medical and recent funding from Trinity Capital highlight Cagent Vascular’s growth trajectory, signaling increasing market credibility and potential for joint ventures or co-marketing arrangements to penetrate broader clinical markets.

Financial Growth Signal Securing $15 million in growth capital demonstrates investor confidence and market validation, providing a foundation for scaling sales efforts, expanding geographic reach, and increasing adoption of its innovative vessel dilation devices.

Market Positioning Focusing on high-impact sectors such as Peripheral Artery Disease and Critical Limb Ischemia with innovative, minimally invasive devices, Cagent Vascular is well-positioned to capitalize on ongoing market trends toward improved interventional therapies and endovascular procedures.